JP2013527242A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527242A5
JP2013527242A5 JP2013513339A JP2013513339A JP2013527242A5 JP 2013527242 A5 JP2013527242 A5 JP 2013527242A5 JP 2013513339 A JP2013513339 A JP 2013513339A JP 2013513339 A JP2013513339 A JP 2013513339A JP 2013527242 A5 JP2013527242 A5 JP 2013527242A5
Authority
JP
Japan
Prior art keywords
compound
coor
group
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013513339A
Other languages
English (en)
Japanese (ja)
Other versions
JP5752789B2 (ja
JP2013527242A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/038879 external-priority patent/WO2011153315A1/en
Publication of JP2013527242A publication Critical patent/JP2013527242A/ja
Publication of JP2013527242A5 publication Critical patent/JP2013527242A5/ja
Application granted granted Critical
Publication of JP5752789B2 publication Critical patent/JP5752789B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013513339A 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体 Expired - Fee Related JP5752789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35133810P 2010-06-04 2010-06-04
US61/351,338 2010-06-04
PCT/US2011/038879 WO2011153315A1 (en) 2010-06-04 2011-06-02 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Publications (3)

Publication Number Publication Date
JP2013527242A JP2013527242A (ja) 2013-06-27
JP2013527242A5 true JP2013527242A5 (enExample) 2014-07-17
JP5752789B2 JP5752789B2 (ja) 2015-07-22

Family

ID=44627236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513339A Expired - Fee Related JP5752789B2 (ja) 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体

Country Status (12)

Country Link
US (1) US8754068B2 (enExample)
EP (1) EP2576585B8 (enExample)
JP (1) JP5752789B2 (enExample)
CN (1) CN103038245B (enExample)
AR (1) AR081637A1 (enExample)
BR (1) BR112012030818A2 (enExample)
CA (1) CA2801487C (enExample)
EA (1) EA022393B1 (enExample)
ES (1) ES2612452T3 (enExample)
MX (1) MX2012013703A (enExample)
TW (1) TW201201793A (enExample)
WO (1) WO2011153315A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
CN103037692B (zh) 2010-05-20 2015-02-25 爱荷华大学研究基金会 用于抑制肌萎缩的方法
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
SI2670764T1 (sl) * 2011-01-31 2016-03-31 Bristol-Myers Squibb Company C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv
AU2012268036B2 (en) 2011-06-06 2017-04-06 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS Methods of inhibiting muscle atrophy
MX2014002936A (es) 2011-09-21 2014-04-25 Bristol Myers Squibb Co Nuevos derivados de acido betulinico con actividad antiviral.
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
US20140221361A1 (en) * 2013-02-06 2014-08-07 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
CN105102468A (zh) * 2013-02-25 2015-11-25 百时美施贵宝公司 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
BR112017009850A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112017009853A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, uso de uma quantidade melhoradora de hiv de um composto
KR20170092581A (ko) 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 C17-아릴 치환된 베툴린산 유사체
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
KR20180028535A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
JP2019502728A (ja) 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有するルパンのアミン誘導体
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
PT3478662T (pt) * 2016-06-30 2020-12-09 Viiv Healthcare Uk No 5 Ltd Derivados de azadecalina como inibidores da replicação do vírus da imunodeficiência humana
US20190307776A1 (en) 2016-06-30 2019-10-10 Viiv Healthcare Uk (No. 5) Limited Aza-substituted inhibitors of human immunodeficiency virus replication
EP3784349B1 (en) 2018-04-24 2023-12-27 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
ES2281960T3 (es) * 1998-03-02 2007-10-01 The University Of North Carolina At Chapel Hill Derivados acilados de betulina y dihidrobetulina, su preparacion y su uso.
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
NZ538896A (en) * 2002-09-26 2007-10-26 Niigata University Of Pharmacy Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
JP4722031B2 (ja) * 2003-02-11 2011-07-13 ノベリックス・ファーマシューティカルズ・インコーポレイテッド 腫瘍増殖を阻害するための医薬
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
US20060019934A1 (en) * 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
EP1986654A2 (en) * 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) * 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009020732A1 (en) * 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
WO2009042166A1 (en) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
WO2009114083A2 (en) 2008-03-03 2009-09-17 Panacos Pharmaceuticals, Inc. Determinants of antiviral response
WO2009129548A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US20120302534A1 (en) * 2010-02-11 2012-11-29 Daxin Gao Derivatives of betulin

Similar Documents

Publication Publication Date Title
JP2013527242A5 (enExample)
JP2013527243A5 (enExample)
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
JP2014503595A5 (enExample)
JP2013510124A5 (enExample)
JP2015510515A5 (enExample)
JP2009507896A5 (enExample)
HRP20171512T1 (hr) Derivati betulina
RU2012146777A (ru) Макроциклические ингибиторы интегразы
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
JP2013542247A5 (enExample)
SI2935307T1 (en) Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
JP2014508753A5 (enExample)
JP2013518107A5 (enExample)
ME02666B (me) Cefalosporin sa kateholskom grupom
JP2017501205A5 (enExample)
ME02321B (me) Antivirusna jedinjenja
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
AR077435A1 (es) Composiciones dermatologicas de antagonistas del receptor dp2 y uso
JP2017537066A5 (enExample)
HRP20210813T1 (hr) Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi
JP2010077141A5 (enExample)
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
JP2013507423A5 (enExample)